Macau University of Science and Technology

Hong Kong Baptist University

The Hong Kong University of Science and Technology

Fujian South Pharmaceutical Co., Ltd.

Zhihong Jiang

Liang Liu

Jingrong Wang

Hua Zhou

Kam Wai Wong

Liping Bai

Dan Dan Wang

Hang Dong

Jidong Yang

Huaxing Zhan

Xin Shen

Ting Li

Pei Luo

Zhiling Yu

Chun Liang

Wai In Chan

Yuan Ma

Fei Ren

Ziyi Wang

Zhongqiu Liu

Pengfei Miao

Min Du

Hongsheng Zhang

Jianping Luo

Dan Wang

A use offungal RNA molecules, a drug, a drug composition and a delivery carrier are provided. It has been proved that the tRFs derived from thetraditional Chinese medicine has an obvious inhibiting effect on airway smooth muscle cell phenotype change (proliferation, abnormal secretion and the like) induced by TGF-β1 and AHR, inflammation and remodeling of asthma mice induced byin the experiments of the present disclosure, which suggests that the tRFs derived from thetraditional Chinese medicine and a pharmaceutical composition can be a brand new medicine for treating asthma. The drug comprises the RNA molecule and a pharmaceutically acceptable carrier, diluent and/or excipient. The present disclosure is helpful for the research and development of asthma treatment drugs and provides reference for the research and development of other respiratory system disease treatment drugs.

Use of ganoderma fungal RNA molecules, drug, drug composition and delivery carrier

A method for treating cancer by using an agent which is capable of inhibiting the functionality of the MCM complex, a heterohexameric ring formed from six subunits, in the process of DNA replication and a method of screening for such agents by detecting the locations and functions of the MCM subunits, such as hMcm2 and hMcm6, in cells treated with candidate compounds.

Method and compounds for inhibiting the MCM complex and their application in cancer treatment

The present invention provides an in vivo platform for identifying and determining therapeutic or prophylactic activity of test compounds in delay-type hypersensitivity (DTH) and other inflammatory or cancerous diseases mediated by activation of IKK-&#x3b2;mutants. The in vivo platform of the present invention is a non-human transgenic mammal, e.g., a mouse model, with a site directed mutagenesis at a cysteine residue replaced by alanine in IKK-&#x3b2; protein kinase. The site directed mutagenesis is introduced by a specially designed targeting vector containing a transversion in exon 3 of the Ikbkb genes encoding the IKK-&#x3b2;. The present invention also provides methods for generating the transgenic mammal and for determining and identifying compounds that can inhibit activation of IKK-&#x3b2;mutants.

Transgenic model for delay-type hypersensitivity (DTH) and use thereof

A saponin nano micelle, preparing method, application and pharmaceutical composition thereof is disclosed in the present invention. The saponin nano micelle comprises one or more of saponins represented by formula 1, in which, Rand Rare independently &#x2014;H or a hydrophilic group, Ris &#x2014;H or &#x2014;OH, Ris a lipophilic group. The preparing method of the saponin nano micelle is that mixing the saponin with an organic solvent which can dissolve saponin, and then removing the organic solvent. The saponin micelle acts as a convey medium of the drug ingredients, and can replace conventional drug carriers such as pharmaceutical solubilizers or polymeric micelle, which has high safety and great significance. The pharmaceutical ingredients can prolong circulation time and biological half-life of drug in the blood, and increase the accumulation of drug in lesions, and reduce adverse reactions. 

Saponin nano micelle, preparing method, application and pharmaceutical composition thereof

The present invention provides novel ginsenoside derivative compounds and the use thereof in protection against ischemia/reperfusion injury.

Ginsenoside derivative compounds and the use thereof in protection against ischemia/reperfusion injury

The present invention relates to a novel compound derived from ginsenoside Rh2, the preparation methods and the use thereof in treating cancers.

Ginsenoside with anti-cancer activity and the preparation method thereof

Two hitherto unreported novel hemiterpene glycosides were isolated in substantially pure form from the root of. The chemical structures and some properties of these hemiterpenes have been elucidated. These hemiterpene glycosides possess anti-platelet aggregation activity more potent than those of salvianolic acid B and aspirin and may be used in pharmaceutical compositions in humans and mammals in need of such treatment.

[object Object]

Growing community of inventors

Macao, China

Zhihong Jiang